Update shared on 09 Nov 2025
Fair value Decreased 6.61%QuidelOrtho's analyst price target has been lowered from $40.33 to $37.67. This reflects adjustments to discount rates and margin forecasts as analysts re-evaluate the company's outlook.
What's in the News
- QuidelOrtho provided its fiscal 2025 financial guidance, forecasting total revenues between $2.68 billion and $2.74 billion (Corporate Guidance).
- The U.S. FDA granted 510(k) clearance for the VITROS hs Troponin I Assay, which aids in diagnosing myocardial infarction. The assay will be available to U.S. laboratories later this year (Product-Related Announcement).
- The QUICKVUE portfolio expanded with the CLIA-waived QUICKVUE Influenza + SARS Test. This test enables rapid, simultaneous detection of influenza A, influenza B, and COVID-19 for professional use (Product-Related Announcement).
- The company launched a Certified Analyzer Program to bring certified VITROS analyzers and reliable diagnostic testing to rural and community hospitals across the United States (Product-Related Announcement).
Valuation Changes
- Consensus Analyst Price Target fell modestly from $40.33 to $37.67 per share.
- The discount rate increased from 10.56 percent to 12.46 percent, indicating heightened perceived risk.
- The revenue growth forecast rose slightly from 2.61 percent to 3.12 percent.
- The net profit margin estimate edged down from 0.58 percent to 0.57 percent.
- The future P/E ratio decreased marginally from 219.23x to 218.38x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.